Pharma Companies Announce Investments in R&D, Ongoing Clinical Trials and Financial Results - Research Report on Alnylam, Infinity, Nektar, Sequenom, and Merrimack

NEW YORK, August 15, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Sequenom Inc. (NASDAQ: SQNM), and Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Alnylam Pharmaceuticals, Inc. Research Report

On August 8, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) reported its consolidated Q2 2013 financial results with total revenues of $8.7 million, compared to $20.9 million in Q2 2012. R&D expenses increased by 11.5% YoY to $24.2 million and GAAP net loss for the quarter totaled $18.2 million, or $0.29 per share, compared to a net loss of $13 million, or $0.25 per share, in Q2 2012. Michael Mason, Vice President, Finance and Treasurer of Alnylam said, "Alnylam continues to maintain a solid balance sheet, ending this second quarter with $380 million in cash. We remain on track to end 2013 with greater than $320 million, which will continue to provide us with a strong balance sheet to execute on our business plan and advance our RNAi therapeutics through clinical trials and toward the market." Alnylam anticipates that its cash, cash equivalents and total marketable securities balance will be more than $320 million at December 31, 2013. The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-13/ALNY]

Infinity Pharmaceuticals, Inc. Research Report

On August 8, 2013, Infinity Pharmaceuticals Inc. (Infinity) reported its Q2 2013 financial results with no revenue recorded for the period compared to revenue of $21.9 million in Q2 2012. Infinity informed that Q2 2012 revenue was mainly composed of reimbursed research and development (R&D) services performed under a previous strategic alliance with Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Limited. Net loss for the quarter totaled $32.6 million or $0.68 per share against $14.7 million or $0.54 per share in Q2 2012. R&D expenses totaled $26.1 million compared to $28.5 million in Q2 2012, which decreased primarily due to the discontinuation of the development of Hedgehog pathway program. For 2013, the Company anticipates net loss in the range of $135 million to $145 million. The Full Research Report on Infinity Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-13/INFI]

Nektar Therapeutics Research Report

On August 8, 2013, Nektar Therapeutics (Nektar) reported its Q2 2013 financial results with revenue of $33.9 million compared to $23.7 million in Q2 2012. Net loss for the quarter totaled $42.7 million or $0.37 loss per share, compared to $34.3 million or $0.30 loss per share in Q2 2012. R&D expenses totaled $52.2 million compared to $33.2 million in Q2 2012. According to Nektar, the increase in R&D expenses reflected the costs of different clinical trials. Howard W. Robin, President and CEO of Nektar said, "I am very pleased with Nektar's performance this year. We are on track to report high-level results from the Phase 2 efficacy study of NKTR-181 in chronic pain patients this summer. Finally, we recently completed enrollment in our Phase 3 study of NKTR-102 ahead of schedule." The Full Research Report on Nektar Therapeutics - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-13/NKTR]

Sequenom Inc. Research Report

On August 1, 2013, Sequenom Inc. (Sequenom) and CombiMatrix Corp. jointly announced that the Sequenom Center for Molecular Medicine LLC and CombiMatrix have entered into a collaboration agreement to market chromosomal microarray analysis (CMA) testing services to widen and confirm the results of noninvasive, prenatal testing (NIPT) to physicians and their patients. Bill Welch, President and COO of Sequenom, Inc. said, "The MaterniT21 PLUS test is the premier, noninvasive prenatal test on the market today, and for an important group of patients a chromosomal microarray test can be a significant adjunct for a comprehensive prenatal analysis. CombiMatrix specializes in CMA and their technology helps further expand our product offering in the growing prenatal genetic testing marketplace." The Full Research Report on Sequenom Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-13/SQNM]

Merrimack Pharmaceuticals, Inc. Research Report

On August 8, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) reported its Q2 2013 financial results with collaboration revenues of $18.5 million compared to $12.1 million in Q2 2012. Net loss for the quarter totaled $30.3 million or $0.31 per share compared to net loss of $20.1 million or $0.22 per share in Q2 2012. R&D expenses totaled $42.5 million compared to $28.8 million in Q2 2012. Merrimack informed that the increase in R&D expenses is primarily attributable to ongoing clinical trials. Robert Mulroy, President and CEO of Merrimack said, "We are pleased with a strong quarter of progress advancing our pipeline of six novel therapeutic candidates. We remain on track for a robust set of milestones in the months ahead and we remain focused on our goal of delivering transformative therapies to patients to dramatically improve cancer outcomes." The Full Research Report on Merrimack Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-13/MACK]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.InvestorsReports.com

SOURCE Investors' Reports